- Home
- PC vs CTMX Comparison
PC vs CTMX Comparison
Compare PC & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PC
- CTMX
- Stock Information
- Founded
- PC 2012
- CTMX 2008
- Country
- PC Singapore
- CTMX United States
- Employees
- PC N/A
- CTMX N/A
- Industry
- PC Restaurants
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- PC Consumer Discretionary
- CTMX Health Care
- Exchange
- PC Nasdaq
- CTMX Nasdaq
- Market Cap
- PC 74.4M
- CTMX 89.1M
- IPO Year
- PC 2024
- CTMX 2015
- Fundamental
- Price
- PC $3.00
- CTMX $1.16
- Analyst Decision
- PC
- CTMX Buy
- Analyst Count
- PC 0
- CTMX 6
- Target Price
- PC N/A
- CTMX $5.77
- AVG Volume (30 Days)
- PC 237.3K
- CTMX 694.5K
- Earning Date
- PC 11-15-2024
- CTMX 11-05-2024
- Dividend Yield
- PC N/A
- CTMX N/A
- EPS Growth
- PC N/A
- CTMX N/A
- EPS
- PC N/A
- CTMX 0.13
- Revenue
- PC $4,118,064.00
- CTMX $119,569,000.00
- Revenue This Year
- PC N/A
- CTMX $1.96
- Revenue Next Year
- PC N/A
- CTMX N/A
- P/E Ratio
- PC N/A
- CTMX $8.62
- Revenue Growth
- PC N/A
- CTMX 50.41
- 52 Week Low
- PC $3.00
- CTMX $1.04
- 52 Week High
- PC $5.73
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- PC N/A
- CTMX 48.86
- Support Level
- PC N/A
- CTMX $1.12
- Resistance Level
- PC N/A
- CTMX $1.19
- Average True Range (ATR)
- PC 0.00
- CTMX 0.05
- MACD
- PC 0.00
- CTMX 0.00
- Stochastic Oscillator
- PC 0.00
- CTMX 50.00
About PC Premium Catering (Holdings) Limited Ordinary Shares
Premium Catering (Holdings) Ltd is a company that conducts its operations through its subsidiary is mainly engaged in food catering for functions, events, and workers in Singapore. They specialize in Indian, Bangladesh, and Chinese cuisine and all its food products are Halal food which is permissible for consumption by Muslims to consume.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.